Previous 10 | Next 10 |
SAN DIEGO , Oct. 2, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive ...
SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
Heron Therapeutics (NASDAQ: HRTX ) has resubmitted its NDA to the FDA for HTX-011, an investigational agent for the management of postoperative pain. The Company anticipates a 6-month review by the FDA. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Read more ...
SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...
SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
Good investors spread their bets across a wide spectrum of assets , which is why this list of picks from top Wall Street investors is so interesting. Not only are some of the smartest people in finance buying these three stocks, but the opportunities highlighted here by big-name investors, note...
Heron Therapeutics ( HRTX -0.5% ) announces positive results from a Phase 3 clinical trial, EPOCH 2 , evaluating HTX-011 for the management of pain in patients undergoing hernia repair surgery. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Read more ...
SAN DIEGO , Aug. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
Trust is always a good idea. For someone else. " - Sherrilyn Kenyon Second quarter results continue to hit the wires in a fast and furious manner. Given the recent turmoil in the market, investors can be forgiven for overlooking many good results from small-cap concerns. The market has ha...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...